Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 25, 2021
Reporting Period: Quarter and fiscal year ended December 31, 2020
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the referenced press release (Exhibit 99.1) and are not provided in the source text.
Material Changes
The filing does not provide specific data to compare current period results against prior comparable periods. It solely references the announcement of results for the period ended December 31, 2020.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 25, 2021, announcing financial results for the quarter and fiscal year ended December 31, 2020.
Legal Disclaimer: The information in this Current Report (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 25, 2021) for specific revenue, net loss, and cash position figures.
- Verify the Company's status as an Emerging Growth Company and any associated accounting election impacts.
- Confirm the trading symbol (VVOS) and exchange (NASDAQ) for current market data.
- Check subsequent filings for detailed financial statements if not fully disclosed in the press release.